PharmaEssentia Corporation (LUX:261280523)

Luxembourg flag Luxembourg · Delayed Price · Currency is EUR · Price in USD
16.80
-0.20 (-1.18%)
At close: Sep 26, 2025
-1.18%
Market Cap5.33B
Revenue (ttm)367.88M
Net Income (ttm)117.96M
Shares Outn/a
EPS (ttm)0.32
PE Ratio45.15
Forward PE28.19
Dividend0.02 (0.11%)
Ex-Dividend DateAug 11, 2025
Volumen/a
Average Volumen/a
Openn/a
Previous Close17.00
Day's Rangen/a
52-Week Range13.58 - 23.57
Betan/a
RSI50.48
Earnings DateNov 13, 2025

About PharmaEssentia

PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutro... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1990
Employees 131
Stock Exchange Luxembourg Stock Exchange
Ticker Symbol 261280523
Full Company Profile

Financial Performance

Financial numbers in TWD Financial Statements

News

There is no news available yet.